- Oops!Something went wrong.Please try again later.
Shares of IDEXX Laboratories (NASDAQ:IDXX) were unchanged after the company reported Q4 results.
Earnings per share were up 69.23% year over year to $1.76, which beat the estimate of $1.40.
Revenue of $720,938,000 rose by 19.08% from the same period last year, which beat the estimate of $681,020,000.
The upcoming fiscal year's EPS expected to be between $7.39 and $7.71.
The upcoming fiscal year's revenue expected to be between $3,065,000,000 and $3,120,000,000.
How To Listen To The Conference Call
Date: Feb 02, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/xk7zt4ee
Company's 52-week high was at $516.87
Company's 52-week low was at $168.65
Price action over last quarter: Up 15.91%
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. Idexx gets about 38% of its revenue from outside the United States.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.